The role of individual susceptibility in cancer burden related to environmental exposure

Environmental Health Perspectives

Volumn 104, Issue SUPPL. 3, 1996, Pages 569-577

  Bartsch, Helmut ^a   Hietanen, Eino ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adducts; Genotypes; Lung cancer; Metabolism; Polymorphism

Indexed keywords

PROTEIN P53;

CANCER SUSCEPTIBILITY; CONFERENCE PAPER; DETOXIFICATION; DNA REPAIR; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; LUNG CANCER; METABOLISM; NUCLEIC ACID BASE SUBSTITUTION; NUTRITIONAL STATUS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0029990683     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.96104s3569     Document Type: Conference Paper

References (99)

1. Doll R, Peto R. The causes of cancer. Quantitative estimates of avoidable risks of cancer in the United States today. Oxford:Oxford University Press, 1981.
2. Perera FP, Santella R. Carcinogenesis. In: Molecular Epidemiology, Principle and Practices (Schulte PA, Perera FP, eds). San Diego:Academic Press, 1993;277-300.
3. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127 (1992).
4. Ingelman-Sundberg M, Johansson I, Persson I, Yue Q-Y, Dahl ML, Bertilsson L, Sjöqvist F. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 2:264-271 (1992).
5. Shields PG, Sugimura H, Caporaso NE, Petruzzelli SF, Bowman ED, Trump BF, Weston A, Harris CC. Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Health Perspect 98:191-194 (1992).
6. Bell DA, Taylor JA, Butler MA, Stephens E, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14:1689-1692 (1993).
7. Bertilsson L, Dahl M-L, Sjöqvist F, Aberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [Letter]. Lancet 341:63 (1993).
8. Lin HJ, Han C-Y, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics and whites: application to metabolic epidemiology. Am J Hum Genet 52:827-834 (1993).
9. Bartsch H, Rojas M, Alexandrov K, Camus A-M, Castegnaro M, Malaveille C, Anttila S, Hirvonen K, Husgafvel-Pursiainen K, Hietanen E, Vainio H. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. Pharmacogenetics 5:S84-S90 (1995).
10. Kaderlik KR, Kadlubar FF. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Pharmacogenetics 5:S108-S117 (1995).
11. Rannug A, Alexandrie A-K, Petersson I, Ingelman-Sundberg M. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 37:25-36 (1995).
12. Pelkonen O, Nebert DW. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev 34:189-222 (1982).
13. Alexandrov K, Rojas M, Geneste O, Castegnaro M, Camus AM, Petruzzelli S, Giuntini C, Bartsch H. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smoker's lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res 52:6248-6253 (1992).
14. 32P-postlabelling and ELISA. Carcinogenesis 15:557-560 (1994).
15. Phillips DH, Hewer A, Martin CN, Garner RC, King MM. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 336:790-792 (1988).
16. Phillips DH, Schoket B, Hewer A, Bailey E, Kostic S, Vincze I. Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int J Cancer 46:569-575 (1990).
17. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 54:5801-5803 (1994).
18. Rojas M, Alexandrov K, Auburtin G, Wastiaux-Denamur A, Mayer L, Mahieu B, Sebastien P, Bartsch H. Antibenzo[a]pyrene diol epoxide-DNA adduct levels in peripheral mononuclear cells from coke oven workers and the enhancing effect of smoking. Carcinogenesis 16:1373-1376 (1995).
19. Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In: Chemical Carcinogenesis and Mutagenesis I (Cooper CS, Grover PL, eds). Berlin, Heidelberg:Springer, 1990;63-103.
20. Hecht SS, Carmella SG, Murphy SE, Idris AM, Richie JP Jr, Hoffmann D. Recent studies on tobacco-specific nitrosamines [Abstract]. In: Proceedings of the XVI International Cancer Congress, 30 October-5 November 1994, New Delhi, India. New Delhi:Allied Publishers Ltd., 1994;222.
21. 2-Ethenodeoxyguanosine as a potential marker for DNA adduct formation by trans-4-hydroxy-2-nonenal. Cancer Res 48:320-323 (1988).
22. Bartsch H, Barbin A, Marion M-I, Nair J, Guichard Y. Formation, detection, and role in carcinogenesis of ethenobases in DNA. Drug Metab Rev 26:349-369 (1994).
23. 4-ethenocytosine by lipid peroxidation products and nucleic acid bases. Chem Res Toxicol 8:278-283 (1995).
24. 32P-postlabelling. Carcinogenesis 16:613-617 (1995).
25. Norppa H, Hirvonen A, Järventaus H, Uusküla M, Tasa G, Ojajärvi A, Sorsa M. Role of GSTT1 and GSTM1 genotypes in determining individual sensitivity to sister chromatid exchange induction by diepoxybutane in cultured human lymphocytes. Carcinogenesis 16:1261-1264 (1995).
26. Wiencke JK, Pemble S, Ketterer B, Kelsey KT. Gene deletion of glutathione S-transferase θ: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epidemiol Biomarkers Prev 4:253-259 (1995).
27. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenorype and an RFLP. Am J Hum Genet 48:720-725 (1990).
28. 2) allele or CYP1A1 inducibility in a three-generation family of east Mediterranean descent. Pharmacogenetics 4:21-26 (1994).
29. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SI. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963 (1994).
30. Landi MT, Bertazzi PA, Shields PG, Clark G, Lucier GW, Garte SJ, Cosma G, Caporaso NE. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacokinetics 4:242-246 (1994).
31. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 263:131-133 (1990).
32. Nakachi K, Imai K, Hayashi S, Kawajiri K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53:2994-2999 (1993).
33. Hayashi SI, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J Biochem 110:407-411 (1991).
34. Hayashi S, Watanabe J, Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and mu-class glutathione S-transferase genes. Jpn J Cancer Res 83:866-870 (1992).
35. Tefre T, Ryberg D, Haugen A, Nebert DW, Skaug V, Brogger A, Borresen AL. Human CYP1A1 (cytochrome P1450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1:20-25 (1991).
36. Hirvonen A, Husgafvel-Pursiainen K, Karjakinen A, Anttila S, Vainio, H. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1:485-489 (1992).
37. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53:503-514 (1993).
38. Fernandez-Salquero P, Gonzalez FJ. The CYP2A gene family: species differences, regulation, catalytic activities and role in carcinogenesis. Pharmacogenetics 5:S123-128 (1995).
39. Tiano HF, Wang R-L, Hosokawa M, Crespi C, Tindall KR, Langenbach R. Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): mutational specificity in the gpt gene of AS52 cells. Carcinogenesis 15:2859-2866 (1994).
40. Uematsu F, Kikuchi H, Motomiya M, Abe T, Sagami I, Ohmachi T, Wakui A, Kanamaru R, Watanabe M. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res 82:254-256 (1991).
41. Kato S, Shields PG, Caporaso NE, Hoover RN, Trump BF, Sugimura H, Weston A, Harris CC. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52:6712-6715 (1992).
42. Persson I, Johansson I, Bergling H, Dahl ML, Seidegård J, Rylander R, Rannung A, Högberg J, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer. FEBS Lett 319:207-211 (1993).
43. Peyronneau MA, Renaud JP, Jaouen M, Urban P, Cullin C, Pompon D, Mansuy D. Expression in yeast of three allelic cDNAs coding for human liver P-450 3A4. Different stabilities, binding properties and catalytic activities of the yeast-produced enzymes. Eur J Biochem 218:355-361 (1993).
44. Kivistö KT, Griese E-U, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P, Kroemer HK. Expression of cytochrome P4503A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn-Schmiederberg's Arch Pharmacol 353:207-212 (1996).
45. Landers JP, Bunce NJ. The Ah receptor and the mechanism in dioxin toxicity. Biochem J 276:273-287 (1991).
46. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O. Cloning of a factor required for the activity of the Ah (dioxin) receptor. Science 252:954-958 (1991).
47. Johnson BS, Brooks BA, Reyes H, Hoffman EC, Hankinson O. An MspI RFLP in the human ARNT gene, encoding a subunit of the nuclear form of the Ah (dioxin) receptor. Human Mol Genet 1:351 (1992).
48. Hayashi SI, Watanabe J, Nakachi K, Eguchi H, Gotoh O, Kawajiri K. Interindividual difference in expression of human Ah receptor and related P450 genes. Carcinogenesis 15:801-806 (1994).
49. Coles B, Ketterer B. The role of glutathione and glutathione transferase in chemical carcinogenesis. CRC Crit Rev Biochem Mol Biol 25:47-70 (1990).
50. Seidegård J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of the human glutathione transferase active on trans-stilben oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297 (1988).
51. Bell DA, Thompson CL, Taylor J, Miller CR, Perera F, Hsieh LL, Lucier GW. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase μ. Environ Health Perspect 98:113-117 (1992).
52. Nakajima T, Elovaara E, Anttila S, Hirvonen A, Camus A-M, Hayes JD, Ketterer B, Vainio H. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis 16:707-711 (1995).
53. Kadlubar FF, Butler MA, Kaderlik KR, Chou H-C, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 98:69-74 (1992).
54. Seidegård J, Pero RW, Miller DG, Beattie EJ. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 7:751-753 (1986).
55. Seidegård J, Pero RW, Markowitz MM, Roush G, Miller GD, Beattie EJ. Isozyme(s) of glutathione transferase (class mu) as a marker for the susceptibility to lung cancer: a follow up study. Carcinogenesis 11:33-36 (1990).
56. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP, Kadlubar FF. The glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 98:87-94 (1992).
57. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR, Spurr NK. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12:1533-1537 (1991).
58. Brockmöller J, Kerb R, Drakoulis N, Nitz M, Roots I. Genotype and phenotype of glutathione S-transferase class μ isoenzymes μ and ψ in lung cancer patients and controls. Cancer Res 53:1004-1011 (1993).
59. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Vainio H. The CSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 14:1479-1481 (1993).
60. Redford-Ellis M, Govenlock AH. Studies on the reaction of chloromethane with human blood. Acta Pharmacol Toxicol 30:36-48 (1971).
61. Peter H, Deutschmann S, Reichel C, Hallier E. Metabolism of methyl chloride by human erythrocytes. Arch Toxicol 63:351-355 (1989).
62. Hallier E, Deutschmann S, Reichel C, Bolt HM, Peter H. A comparative investigation of the metabolism of methyl bromide and methyl iodide in human erythrocytes. Int Arch Occup Environ Health 62:221-225 (1990).
63. Thier R, Föst U, Deutschmann S, Schröder KR, Westphal G, Hallier E, Peter H. Distribution of methylene chloride in human blood. Arch Toxicol 14:254-258 (1991).
64. Thier R, Taylor JB, Pemble SE, Griffith-Humphreys W, Persmark M, Ketterer B, Guengerich FP. Expression of mammalian glutathione S-transferase 5-5 in Salmonella, typhimurium TA 1535 leads to base-pair mutations upon exposure to dihalomethanes. Proc Natl Acad Sci 90:8576-8580 (1993).
65. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300:271-276 (1994).
66. Guengerich FP. Epoxide hydrolase: properties and metabolic roles. Rev Biochem Toxicol 4:5-30 (1982).
67. Jerina DM. Metabolism of aromatic hydrocarbons by the cytochrome P-450 system and epoxide hydrolase. Drug Metab Dispos 11:1-4 (1983).
68. Gonzalez FJ, Samore M, McQuiddy P, Kasper CB. Effects of 2-acetaminofluorene and N-hydroxy-2-acetaminofluorene on the cellular levels of epoxide hydrolase, cytochrome p-450b, and NADPH-cytochrome c (P-450) oxidoreductase messenger ribonucleic acids. J Biol Chem 257:11032-11036 (1982).
69. Wood AW, Chang RL, Levin W, Yagi H, Thakker DR, van Bladderen PJ, Jerina DM, Conney AH. Mutagenicity of the enantiomer of the diastomeric bay-region benz(a)anthracene 3,4-diol-1,2-epoxides in bacterial and mammalian cells. Cancer Res 43:5821-5825 (1983).
70. Seidegård J, DePierre JW. Microsomal epoxide hydrolase: properties, regulation and function. Biochim Biophys Acta 695:251-270 (1983).
71. Hasset C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3:421-428 (1994).
72. Jin C-J, Miners JO, Burchell B, Mackenzie PI. The glucuronidation of hydroxylated metabolites of benzo(a)pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. Carcinogenesis 14:2637-2639 (1993).
73. Owens TS, Ritter JK. The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple familial hyperbilirubinaemia phenotypes. Pharmacogenetics 2:93-108 (1992).
74. Burchell B, Nebert DW, Nelson DR, Bock KW, Iyanagi T, Jansen PLM, Lancet D, Mulder GJ, Chowdhury JR, Siest G, Tephy T, Mackenzie P. The UDP-glucuronosyltransferase gene family: suggested nomenclature based on evolutionary divergence. DNA Cell Biol 10:487-494 (1991).
75. Daly AK, Cholerton S, Gregory W, Idle JR. Metabolic polymorphisms. Pharmacol Ther 57:129-160 (1993).
76. Anttila S, Vainio H, Hietanen E, Camus A-M, Malaveille C, Brun G, Husgafvel-Pursiainen K, Heikkilä L, Karjalainen A, Bartsch H. Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. Environ Health Perspect 98:179-182 (1992).
77. Ichiba M, Hagmar L, Rannug A, Högstedt B, Alexandrie A-K, Hemminki K. Aromatic DNA adducts, micronuclei and genetic polymorphism for CYP1A1 and GST1 in chimney sweeps. Carcinogenesis 15:1347-1352 (1994).
78. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I, Borresen A-L, Haugen A. p53-mutations in lung tumors. Relationship to putative susceptibility markers for cancer. Cancer Res 54:1551-1555 (1994).
79. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:9-53 (1991).
80. Harris C, Hollstein M. Clinical implications of the p53 tumorsuppressor gene. N Engl J Med 329:1318-1327 (1993).
81. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 52:734-736 (1992).
82. Ridanpää M, Karjalainen A, Anttila S, Vainio H, Husgafvel-Pursiainen K. Genetic alterations in p53 and K-ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient. Int J Oncol 5:1109-1117 (1994).
83. Husgafvel-Pursiainen K, Ridanpää M, Anttila S, Vainio H. p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occup Environ Med 37:69-75 (1995).
84. Ionov YM, Peinado A, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequencies reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561 (1993).
85. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin J-P, Järvinen H, Powell SM, Jen J, Hamilton SR, Petersen GM, Kinzler KW, Vogelstein B, de la Chapelle A. Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816 (1993).
86. Wooster R, Cleton-Jansen A-M, Collins N, Mangion J, Cornelis RS, Cooper CS, Gusterson BA, Ponder BAJ, von Deimling A, Wiestler OD, Cornelisse CJ, Devilee P, Stratton MR. Instability of short tandem repeats (microsatellites) in human cancers. Nature Genet 6:152-156 (1994).
87. Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB, Sidransky D. Frequent microsatellite instability in primary small cell lung cancer. Cancer Res 54:2098-2101 (1994).
88. Shridhar V, Siegfried J, Hunt J, del Mar Alonso M, Smith DI. Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. Cancer Res 54:2084-2087 (1994).
89. Fishel R, Lescoe MK, Rao MRS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038 (1993).
90. Bronner,C.E. Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R, Liskay RM. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258-261 (1994).
91. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopoulos N, Peltomäki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genet 9:48-55 (1995).
92. Harris C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981 (1993).
93. Malkinson AM. The genetic basis of susceptibility to lung tumors in mice. Toxicology 54:241-271 (1989).
94. Dragani TA, Manenti G, Plerotti MA. Genetics of murine lung tumors. Adv Cancer Res 67:83-119 (1995).
95. Gariboldi M, Manenti G, Canzian F, Falvella FS, Radice T, Pierotti MA, Binelli G, Della Porta G, Dragani TA. A major susceptibility locus to murine lung carcinogenesis maps on chromsome 6. Nature Genet 3:132-138 (1993).
96. Sellers TA, Potter JD, Bailey-Wilson JE, Rich SS, Rothschild H, Elston RC. Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. Cancer Res 82:2694-2697 (1992).
97. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 285:2037-2048 (1994).
98. Knudson AG. All in the (cancer) family. Nature Genet 5:103-104 (1993).
99. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 90:10914-10921 (1993).